Cover Image
市場調查報告書

MediPoint:全球核影像診斷市場 (PET、SPECT設備) - 全球市場的分析與預測

MediPoint: Nuclear Imaging - PET and SPECT Equipment - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 331274
出版日期 內容資訊 英文 318 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:全球核影像診斷市場 (PET、SPECT設備) - 全球市場的分析與預測 MediPoint: Nuclear Imaging - PET and SPECT Equipment - Global Analysis and Market Forecasts
出版日期: 2014年12月15日 內容資訊: 英文 318 Pages
簡介

在全球各國醫療改革進行發展,隨著受到醫療費用支出額受抑制的壓力核子醫學攝影診斷技術的市場也受到很大的壓力、影響。隨著現有的正子斷層掃描(PET)技術和單光子發射電腦斷層掃描(SPECT)技術開始成熟化,那些與電腦斷層掃描技術和核磁共振攝影組合技術的產品普及,PET、SPECT專用設備有縮小趨勢。在各地區中,美國是全球最大的市場,不過,預期日本、中國市場今後也將急速成長。

本報告提供全球的核子醫學攝影診斷(PET、SPECT設備等)相關的市場相關分析、疾病概要和市場結構、目前未滿足需求、主要的推動及阻礙市場要素、今後的市場機會、現在臨床實驗中的主要產品、全球整體及主要10個國家的市場趨勢(過去3年的實際成果值和今後7年的預測值)、各類型產品的詳細趨勢、主要企業簡介等調查

第1章 目錄

第2章 簡介

第3章 產業概要

  • 放射性影像技術
    • 正子斷層掃描 (PET)
    • 單光子發射電腦斷層掃描(SPECT)
    • 平面顯像
    • 混合型影像診斷法
  • 核子醫學攝影技術臨床現場的用途
    • 癌症
    • 心臟病
    • 神經症
    • 感染疾病及發炎
  • 核子醫學攝影診斷技術的優點、缺點
  • 市場進入
    • 產品的生命週期
    • 購買意願決策
    • 設備租賃
    • PET/核磁共振攝影的PET/CT替換
  • 醫療費償付(全球整體及主要10個國家份)
  • 治療趨勢(共10個國家份)
  • 法規上的課題/撤消
  • 企業合併、收購(M&A)及主要的聯盟
  • 經濟影響(美國、歐洲)

第4章 未滿足需求

  • 概要
  • 對於新技術的醫療費償付的改善
  • 缺乏有強制力的臨床指南
  • 患者的舒適性及方便
  • 放射線暴露量的減少
  • 掃描儀的性能改善
  • 影像處理軟體的改善
  • 混合型影像處理的人為風險增加
  • 對新的放射性示蹤物的需求
  • 對設計流程的臨床性輸入的改善

第5章 市場機會分析

  • 更便宜簡單的核子醫學影像設備
  • 在開發中國家的SPECT/CT
  • 遠距放射線醫學服務的需求增加

第6章 市場推動因素及障礙

  • 推動因素:老年人及患病人數的增加
  • 推動因素:醫生的認識度提高
  • 推動因素:防禦性醫療
  • 推動因素:患者的認識
  • 推動因素:任意詢問
  • 推動因素:新的顯影劑
  • 推動因素:癌症診斷檢驗的需求擴大
  • 推動因素:搭配診斷檢驗
  • 障礙:競爭產品的有效性研究
  • 障礙:醫療費償付法案
  • 障礙:發展中國家市場上的核子醫學攝影診斷的需求擴大
  • 障礙:減少不必要的影像診斷之保險公司的遊說
  • 障礙:EMR的保險調查的對象者的擴大
  • 障礙:有效性標準的使用增加
  • 障礙:減少不必要的次序的診療指南
  • 障礙:影像設備的認證
  • 障礙:核醫學技術的不足
  • 障礙:設備、試劑的高成本性
  • 在障礙:放射性醫藥品的成本、供給方面的困難性
  • 障礙:醫療設備的物品稅
  • 障礙:醫院的整合

第7章 競爭評估

  • 概要
  • PET專用設備
    • 概要
    • 產品簡介
    • SWOT分析
  • PET/CT設備
  • PET/核磁共振造影系統
  • SPECT專用設備
  • SPECT/CT設備
  • PET/超音波及SPECT/超音波設備

第8章 開發中產品的評估

  • 概要
  • 發展階段的開發中產品
  • 產品簡介(共11種產品)

第9章 關注臨床檢驗

  • 概要
  • 臨床實驗簡介

第10章 現在及未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • DDD-Diagnostic
    • Digirad
    • GE Healthcare
    • GVI Medical Devices
    • Mediso Medical Imaging Systems
    • NeuroLogica
    • Neusoft Medical Systems
    • NuCare Medical Systems
    • Oncovision
    • Philips Healthcare
    • 島津製作所
    • Siemens Healthcare
    • SurgicEye
    • 東芝 Medical Systems
    • 其他的企業

第11章 市場展望

  • 企業市場佔有率分析(全球整體及主要10個國家份)
  • 各市場部門構成比
    • SPECT及SPECT/CT
    • PET、PET/CT及PET/核磁共振攝影
  • 各地區
    • 全球概要
    • 美國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 日本
    • 巴西
    • 中國
    • 印度

第12章 附錄

圖表一覽

目錄
Product Code: GDME0208MAR

This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine.

The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand on struggling healthcare budgets

PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report

PET imaging uses Positron Emitting radioactive tracers with a short half life, to image metabolically active organs

PET combined with CT allows precise anatomical imaging of the body, identifying diseased areas depending upon the tracer used

PET/CT is most often used for cancer diagnosis

PET/MRI is a new technique that was introduced to reduce patient exposure to radiation

PET only systems are now generally considered obsolete, due to the superior imaging quality of PET/CT

SPECT imaging uses Gamma Emitting radioactive tracers with a longer half life, to image molecular processes in the body

SPECT and SPECT/CT are most often used in cardiology studies

The SPECT and SPECT/CT market is a bigger market than the PET, PET/CT and PET/MRI, because the instruments have been in longer use, are cheaper, and have become the common technique for a wide range of indications

Physicians believe more and more SPECT procedures will be replaced by PET procedures

New developments in hybrid nuclear imaging promise to further increase the utility of hybrid nuclear imaging, while significantly improving patient cost-savings and safety, through reduced need for repeat examinations.

This report focuses on the current and future industry trends within the nuclear medicine market, as well as discussing the promising pipeline products, and assessing the competitive landscape.

Highlights

Key Questions Answered

  • What is the current and future nuclear imaging market outlook in the developed and emerging markets? What trends are affecting the global market for both SPECT and PET imaging systems?
  • Which are the key, high growth markets that manufacturers should seek to expand into? What are the types of products that are most likely to succeed?
  • How many Nuclear Imaging Procedures are carried out in each of the 10 Major Markets? What does this imply for instrument adoption rates?
  • What are the major unmet needs in nuclear imaging? In which areas can manufacturers help meet that need?
  • What factors most influence a physician or hospital in the purchase of new nuclear imaging equipment? How much can a physician influence purchasing decisions?
  • How will reimbursement changes will affect nuclear imaging. How has the Affordable Care Act affected nuclear imaging? How will it affect it in the future?
  • How well are new paradigms in nuclear imaging perceived? What motivates companies to develop a new nuclear imaging modality; physician demand or legislative requirement?

Key Findings

  • Nuclear Imaging is a moderately growing market, with a CAGR of 3.3% for the period to 2020
  • PET/CT, SPECT, SPECT/CT and Scinitgraphy are the major techniques in nuclear imaging
  • US dominates the world market for nuclear imaging equipment
  • US will see lowest growth in nuclear imaging equipment thanks to reimbursement pressures
  • Japan and China will present the greatest opportunities for growth, with respective market shares increasing by 75% and almost 100% during the forecasted period
  • BIC nations will experience the highest growth rates in nuclear imaging equipment during the forecast period
  • Non-PET nuclear imaging procedures in the developed markets (US, 5EU, Japan) likely overall to fall during forecast period, as a result of increasing reimbursement pressures and new technologies
  • PET imaging procedures in all markets likely to increase during the forecast period, despite reimbursement pressures, due to increased number of indications

Scope

  • Overview of Nuclear Imaging, including core technologies, estimated procedure trends and disease overview.
  • Current and Future Players Companies involved in the space with portfolio assessment and SWOT analysis.
  • Pipeline analysis: Comprehensive data split across different stages of development, emerging trends and nuclear imaging devices in development
  • Annualized total nuclear imaging equipment market revenue for SPECT, SPECT/CT, PET, PET/CT and PET/MRI, and procedure data for 2012-2013, and forecast for seven years to 2020
  • Other Key topics covered include identification of unmet needs, implications for the nuclear imaging market and how they may be overcome in the near future, reimbursement and regulatory considerations, evaluating market access for each region covered in the report
  • Analysis of the market opportunities in the Nuclear Imaging market, in addition to Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline in the fields of PET/CT, PET/MRI and SPECT/CT.
  • Develop business strategies by understanding the trends shaping and driving the nuclear imaging market
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the nuclear imaging market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Track device sales in the global and country-specific nuclear imaging markets from 2012-2020
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Nuclear Imaging Techniques
    • 3.1.1. Positron Emission Tomography
    • 3.1.2. Single-Photon Emission Computed Tomography
    • 3.1.3. Planar Scintigraphy
    • 3.1.4. Hybrid Imaging
  • 3.2. Clinical Applications of Nuclear Imaging Technology
    • 3.2.1. Cancer
    • 3.2.2. Cardiology
    • 3.2.3. Neurology
    • 3.2.4. Infection and Inflammation
  • 3.3. Advantages and Disadvantages of Nuclear Imaging Technologies
  • 3.4. Market Access
    • 3.4.1. Product Life Cycle
    • 3.4.2. Purchasing Decisions
    • 3.4.3. Equipment Leasing
    • 3.4.4. Replacement of PET/CT by PET/MRI
  • 3.5. Reimbursement
    • 3.5.1. Overview
    • 3.5.2. US
    • 3.5.3. France
    • 3.5.4. Germany
    • 3.5.5. Italy
    • 3.5.6. Spain
    • 3.5.7. UK
    • 3.5.8. Japan
    • 3.5.9. Brazil
    • 3.5.10. China
    • 3.5.11. India
  • 3.6. Procedure Trends
    • 3.6.1. US
    • 3.6.2. France
    • 3.6.3. Germany
    • 3.6.4. Italy
    • 3.6.5. Spain
    • 3.6.6. UK
    • 3.6.7. Japan
    • 3.6.8. Brazil
    • 3.6.9. China
    • 3.6.10. India
  • 3.7. Regulatory Issues/Recalls
  • 3.8. M&As and Key Partnerships
  • 3.9. Economic Impact
    • 3.9.1. US
    • 3.9.2. Europe

4. Unmet Needs

  • 4.1. Overview
  • 4.2. Improved Reimbursement for New Techniques
  • 4.3. Lack of Binding Clinical Guidelines
  • 4.4. Patient Comfort and Convenience
  • 4.5. Reducing Radiation Exposure
  • 4.6. Improved Scanner Performance
  • 4.7. Image Processing Software Improvements
  • 4.8. Increased Risk of Artifacts in Hybrid Images
  • 4.9. Demand for New Radiotracers
  • 4.10. Improved Clinical Input into the Design Process

5. Market Opportunity Analysis

  • 5.1. Cheaper, Simpler Nuclear Imaging Devices
  • 5.2. SPECT/CT in Developing Countries
  • 5.3. Increased Demand for Teleradiology Services

6. Market Drivers and Barriers

  • 6.1. Driver: Aging Population and Increasing Disease Prevalence
  • 6.2. Driver: Referring Physician Awareness
  • 6.3. Driver: Defensive medicine
  • 6.4. Driver: Patient Awareness
  • 6.5. Driver: Self-Referral
  • 6.6. Driver: New Imaging Agents
  • 6.7. Driver: Increasing Demand for Cancer Diagnostic Tests
  • 6.8. Driver: Companion Diagnostic Testing
  • 6.9. Barrier: Comparative Effectiveness Research
  • 6.10. Barrier: Reimbursement Legislation
  • 6.11. Barrier: Increasing Demand for Nuclear Imaging in Developing Markets
  • 6.12. Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging
  • 6.13. Barrier: Greater Payer Scrutiny of EMRs
  • 6.14. Barrier: Increased Use of Appropriateness Criteria
  • 6.15. Barrier: Practice Guidelines to Reduce Unnecessary Procedures
  • 6.16. Barrier: Imaging Facility Accreditation
  • 6.17. Barrier: Loss of Nuclear Medicine Skills
  • 6.18. Barrier: High Cost of Instruments and Reagents
  • 6.19. Barrier: Radiopharmaceutical Cost and Supply Difficulties
  • 6.20. Barrier: Medical Device Excise Tax
  • 6.21. Barrier: Hospital Consolidation

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Dedicated PET Systems
    • 7.2.1. Overview
    • 7.2.2. Product Profile
    • 7.2.3. SWOT Analysis
  • 7.3. PET/CT Systems
    • 7.3.1. Overview
    • 7.3.2. Product Profiles
    • 7.3.3. SWOT Analysis
  • 7.4. PET/MRI Systems
    • 7.4.1. Overview
    • 7.4.2. Product Profile
    • 7.4.3. SWOT Analysis
  • 7.5. Dedicated SPECT Systems
    • 7.5.1. Overview
    • 7.5.2. Product Profile
    • 7.5.3. SWOT Analysis
  • 7.6. SPECT/CT Systems
    • 7.6.1. Overview
    • 7.6.2. Product Profile
    • 7.6.3. SWOT Analysis
  • 7.7. PET/Ultrasound and SPECT/Ultrasound Systems
    • 7.7.1. Overview
    • 7.7.2. Product Profile
    • 7.7.3. SWOT Analysis

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Pipeline by Phases in Development
  • 8.3. Product Profiles
    • 8.3.1. Brain Biosciences CerePET
    • 8.3.2. ECORAD Dual Modality Imager
    • 8.3.3. FMI Technologies ScintiStar PET/CT
    • 8.3.4. IntraMedical Imaging Marginator Beta Camera
    • 8.3.5. INSERT SPECT/MRI
    • 8.3.6. Nucare/Zecotek Photonics New Generation PET Scanning Device
    • 8.3.7. Philips Healthcare PET Alpha Ring Detector
    • 8.3.8. Photo Diagnostic Systems NeuroPET/CT
    • 8.3.9. SynchroPET Breast PET/MRI
    • 8.3.10. SynchroPET Wrist Scanner
    • 8.3.11. SurgicEye SPECT Hybrid

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. Clinical Trial Profiles

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. DDD-Diagnostic
    • 10.3.2. Digirad
    • 10.3.3. GE Healthcare
    • 10.3.4. GVI Medical Devices
    • 10.3.5. Mediso Medical Imaging Systems
    • 10.3.6. NeuroLogica
    • 10.3.7. Neusoft Medical Systems
    • 10.3.8. NuCare Medical Systems
    • 10.3.9. Oncovision
    • 10.3.10. Philips Healthcare
    • 10.3.11. Shimadzu
    • 10.3.12. Siemens Healthcare
    • 10.3.13. SurgicEye
    • 10.3.14. Toshiba Medical
    • 10.3.15. Other Companies

11. Market Outlooks

  • 11.1. Company Market Share Analysis
    • 11.1.1. Global Overview
    • 11.1.2. US
    • 11.1.3. France
    • 11.1.4. Germany
    • 11.1.5. Italy
    • 11.1.6. Spain
    • 11.1.7. UK
    • 11.1.8. Japan
    • 11.1.9. Brazil
    • 11.1.10. China
    • 11.1.11. India
  • 11.2. Market Segment Share
    • 11.2.1. SPECT & SPECT/CT
    • 11.2.2. PET, PET/CT & PET/MRI
  • 11.3. By Geography
    • 11.3.1. Global Overview
    • 11.3.2. US
    • 11.3.3. France
    • 11.3.4. Germany
    • 11.3.5. Italy
    • 11.3.6. Spain
    • 11.3.7. UK
    • 11.3.8. Japan
    • 11.3.9. Brazil
    • 11.3.10. China
    • 11.3.11. India

12. Appendix

  • 12.1. Abbreviations
  • 12.2. Bibliography
  • 12.3. Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in This Study
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Expert Panel Validation
    • 12.5.3. Stakeholder Survey
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Andrew Thompson, PhD, Senior Analyst
    • 12.7.2. Priya Radhakrishnan, MBA, Director, Medical Devices
    • 12.7.3. Bonnie Bain, PhD, Global Head of Healthcare
  • 12.8. About GlobalData
  • 12.9. Disclaimer

List of Tables

  • Table 1: Applications of Nuclear Imaging
  • Table 2: FDG-PET Diagnostic Accuracy for Specific Cancers
  • Table 3: Potential Clinical Benefits of Hybrid Nuclear Imaging in Cardiology
  • Table 4: Applications of PET Imaging in Non-Cancer Neurology
  • Table 5: Applications of SPECT Imaging in Non-Cancer Neurology
  • Table 6: Characteristics of SPECT, PET, Ultrasound, CT, and MRI
  • Table 7: The Age of Canada's Hospital-Based Medical Technology Inventories, Relative to ECCREI Rules, 2009
  • Table 8: Nuclear Imaging Trends in US, 2012-2020
  • Table 9: Nuclear Imaging Trends in France, 2012-2020
  • Table 10: Nuclear Imaging Trends in Germany, 2012-2020
  • Table 11: Nuclear Imaging Trends in Italy, 2012-2020
  • Table 12: Nuclear Imaging Trends in Spain, 2012-2020
  • Table 13: Nuclear Imaging Trends in UK, 2012-2020
  • Table 14: Nuclear Imaging Trends in Japan, 2012-2020
  • Table 15: Nuclear Imaging Trends in Brazil, 2012-2020
  • Table 16: Nuclear Imaging Trends in China 2012-2020
  • Table 17: Nuclear Imaging Trends in India, 2012-2020
  • Table 18: Recent Device Recalls in the Nuclear Imaging Market
  • Table 19: Recent Key Events in the Nuclear Imaging Market
  • Table 20: Nuclear Imaging Market Drivers and Barriers
  • Table 21: Duplicate Diagnostic Test Incidence in France, Germany, UK, and US
  • Table 22: Dedicated PET Scanners
  • Table 23: Dedicated PET SWOT Analysis
  • Table 24: PET/CT Scanners
  • Table 25: PET/CT SWOT Analysis
  • Table 26: PET/MRI Systems
  • Table 27: PET/MRI SWOT Analysis
  • Table 28: Dedicated SPECT Systems
  • Table 29: Dedicated SPECT SWOT Analysis
  • Table 30: SPECT/CT Systems
  • Table 31: SPECT/CT SWOT Analysis
  • Table 32: SPECT-Ultrasound Systems
  • Table 33: SPECT/Ultrasound SWOT Analysis
  • Table 34: Nuclear Imaging Pipeline, 2014
  • Table 35: CerePET SWOT Analysis
  • Table 36: ECORAD Dual Modality Imager SWOT Analysis
  • Table 37: ScintiStar PET/CT SWOT Analysis
  • Table 38: Marginator SWOT Analysis
  • Table 39: INSERT SPECT-MRI SWOT Analysis
  • Table 40: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis
  • Table 41: PET Alpha Ring Detector
  • Table 42: NeuroPET/CT Scanner SWOT Analysis
  • Table 43: SynchroPET Breast PET/MRI SWOT Analysis
  • Table 44: SynchroPET Wrist Scanner
  • Table 45: SurgicEye SPECT/Ultrasound device SWOT Analysis
  • Table 46: Key Clinical Trials
  • Table 47: Company Profile - DDD-Diagnostic
  • Table 48: DDD-Diagnostic SWOT Analysis
  • Table 49: Company Profile - Digirad
  • Table 50: Digirad SWOT Analysis
  • Table 51: Company Profile - GE Healthcare
  • Table 52: GE Healthcare Product Portfolio
  • Table 53: GE Healthcare SWOT Analysis
  • Table 54: Company Profile - GVI Medical Devices
  • Table 55: GVI Medical Devices SWOT Analysis
  • Table 56: Company Profile - Mediso Medical Imaging Systems
  • Table 57: Mediso Medical Imaging Systems SWOT Analysis
  • Table 58: Company Profile - Neurologica
  • Table 59: Neurologica SWOT Analysis
  • Table 60: Company Profile - Neusoft Medical Systems
  • Table 61: Neusoft Medical Systems SWOT Analysis
  • Table 62: Company Profile - NuCare Medical Systems
  • Table 63: Nucare Medical Systems SWOT Analysis
  • Table 64: Company Profile - Oncovision
  • Table 65: Oncovision SWOT Analysis
  • Table 66: Company Profile - Philips Healthcare
  • Table 67: Philips Healthcare SWOT Analysis
  • Table 68: Company Profile - Shimadzu
  • Table 69: Shimadzu SWOT Analysis
  • Table 70: Company Profile - Siemens Healthcare
  • Table 71: Siemens Healthcare SWOT Analysis
  • Table 72: Company Profile - SurgicEye
  • Table 73: SurgicEye SWOT Analysis
  • Table 74: Company Profile - Toshiba Medical
  • Table 75: Toshiba Medical SWOT Analysis
  • Table 76: Other Companies in the Nuclear Imaging Market, 2014
  • Table 77: Global Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020)
  • Table 78: Global Market Value Forecast by Market Segment for PET, PET/CT & PET/MRI (2012-2020)
  • Table 79: Global Sales of PET and SPECT Imaging Systems, 2012-2020
  • Table 80: United States Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 81: France Market Value Forecast by Market Sub segment (2012-2020)
  • Table 82: Germany Market Value Forecast by Market Sub segment (2012-2020)
  • Table 83: Italy Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 84: Spain Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 85: UK Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 86: Japan Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 87: Brazil Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 88: China Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 89: India Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 90: Primary Research Summary
  • Table 91: Primary Research Participants Affiliation

List of Figures

  • Figure 1: Cyclotron Distribution in 10 Countries
  • Figure 2: Localization of Tumor in Chest Cavity by PET, CT, and PET/CT
  • Figure 3: Mutually Beneficial Effects of PET/MRI Imaging
  • Figure 4: Nuclear Imaging Trends in US, 2012-2020
  • Figure 5: Nuclear Imaging Trends in France, 2012-2020
  • Figure 6: Nuclear Imaging Trends in Germany, 2012-2020
  • Figure 7: Nuclear Imaging Trends in Italy, 2012-2020
  • Figure 8: Nuclear Imaging Trends in Spain, 2012-2020
  • Figure 9: Nuclear Imaging Trends in UK, 2012-2020
  • Figure 10: Nuclear Imaging Trends in Japan, 2012-2020
  • Figure 11: Nuclear Imaging Trends in Brazil, 2012-2020
  • Figure 12: Nuclear Imaging Trends in China, 2012-2020
  • Figure 13: SPECT and PET Imaging Trends in India, 2012-2020
  • Figure 14: Total Medicare Expenditures for Imaging Services Paid Under the Physician Fee Schedule, 2000-2006
  • Figure 15: Imaging Utilization Rates (Number of Outpatient Visits with MRI/CT per 1,000 Persons), by Year in the US
  • Figure 16: Global Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 17: US Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 18: France Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 19: Germany Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 20: Italy Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 21: Spain Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 22: UK Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 23: Japan Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 24: Brazil Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 25: China Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 26: India Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 27: Global Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020)
  • Figure 28: Global Market Value Forecast by Market Segment for PET, PET/CT, and PET/MRI (2012-2020)
  • Figure 29: Global Sales of PET and SPECT Imaging Systems, 2012-2020
  • Figure 30: Global Market Share of Nuclear Imaging, 2012 and 2020
  • Figure 31: United States Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 32: France Market Value Forecast by Market Subsegment (2012-2020)
  • Figure 33: Germany Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 34: Italy Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 35: Spain Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 36: UK Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 37: Japan Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 38: Brazil Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 39: China Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 40: India Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 41: Primary Research Summary
  • Figure 42: Primary Research Participants Affiliation
Back to Top